WALTHAM, Mass.--(BUSINESS WIRE)--NeurAxon Inc., a developer of next generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), announced today the appointment of Robert Medve, M.D., to the newly created position of Chief Medical and Regulatory Officer of the Company. Dr. Medve was most recently Vice President of Science, Research and Development of Lifetree Clinical Research, a clinical research organization focused on clinical trials for pain indications.
